Facebook
Twitter
LinkedIn
Forward
Best Practices in Improving Diagnosis and Treatment of Neurotrophic Keratitis (CE Webcast)
Activity Description and Purpose
Neurotrophic keratitis (NK) is a degenerative corneal disease due to decreased or absent sensory corneal innervation. Early diagnosis and treatment of NK are considered important for restoring epithelial integrity and mitigating progression. In advanced stages of the disease, restoring corneal integrity and preventing recurrent defects can be confounded by an inadequate response to treatment(s), neuropathic comorbidities, and atypical presentations. Case-based education can help identify potential best practices in the diagnosis and treatment of all stages of NK. The desired results of this educational activity are to familiarize clinicians with real-world examples of diagnosing and effectively and safely treating patients with all stages of NK that can be applied to their own practice.
Target Audience
This educational activity is intended for optometrists.
Learning Objectives
After completing this activity, participants will be better able to:
- Integrate corneal sensitivity testing into practice to identify neurotrophic keratitis
- Select appropriate treatment for patients with neurotrophic keratitis using clinical evidence
Faculty
 | Francis S. Mah, MD (Chair) |
 | Douglas K. Devries, OD |
 | Lisa M. Nijm, MD, JD |
Disclosure Policy
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity. All relevant relationships have been mitigated.
Faculty
Douglas K. Devries, OD, is a consultant for AbbVie Inc, Alcon, Avellino, Azura Ophthalmics, Bausch Health, Bruder Healthcare, Dompé US, Inc, Eyevance, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Lumenis, Novartis Pharmaceuticals Corporation, OCuSOFT Inc, Oyster Point Pharma, Inc, ScienceBased Health, Sight Sciences, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, TearLab Corporation, Thea Pharma Inc, and Visus Therapeutics; and is on the speakers bureau for Alcon, Bausch Health, Dompé US, Inc, Eyevance, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Lumenis, Novartis Pharmaceuticals Corporation, OCuSOFT Inc, Oyster Point Pharma, Inc, ScienceBased Health, Sight Sciences, and Sun Pharmaceutical Industries, Inc.
Lisa M. Nijm, MD, JD, is a consultant for AbbVie Inc, Alcon, Amgen Inc, Astellas Pharma Inc, Azura Ophthalmics, Bausch & Lomb Incorporated, Bruder Healthcare, BVI, Carl Zeiss Meditec, Inc, Centricity Vision, Inc, Dompé US, Inc, Harrow, Inc, Johnson & Johnson Vision Care, Inc, Nordic Pharma, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Oyster Point Pharma, Inc, Rayner Intraocular Lenses Limited, Scope, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, Thea Pharma Inc, Trukera, and Visus Therapeutics; is an advisory board member of AbbVie Inc, Alcon, Amgen Inc, Astellas Pharma Inc, Azura Ophthalmics, Bausch & Lomb Incorporated, Bruder Healthcare, BVI, Carl Zeiss Meditec, Inc, Centricity Vision, Inc, Dompé US, Inc, Johnson & Johnson Vision Care, Inc, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Oyster Point Pharma, Inc, Rayner Intraocular Lenses Limited, Scope, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, Thea Pharma Inc, and Trukera; is on the speakers bureau for AbbVie Inc, Amgen Inc, Bausch & Lomb Incorporated, Novartis Pharmaceuticals Corporation, Oyster Point Pharma, Inc, and Sun Pharmaceutical Industries, Inc; is a contracted researcher for Ocular Therapeutix, Inc; and has stock options that have not been exercised in Trukera.
Francis S. Mah, MD, is a consultant for Dompé US, Inc*, Kala Pharmaceuticals, and Kiora Pharmaceuticals, Inc*; is an advisory board member of San Diego Eye Bank; and is a contracted researcher for Kala Pharmaceuticals.
* The financial relationship existed during the last 24 months but has now ended
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
Accreditation Statement
COPE approved for 1.5 CE credits for optometrists.
COPE Course ID: 92970-TD (Asynchronous)
COPE Course Category: Treatment & Management of Ocular Disease
Administrator: 
This activity, COPE Activity Number 129083, is accredited by COPE for continuing education for optometrists.
Disclosure of Commercial Support
MedEdicus LLC has received commercial support from Dompé US, Inc, for this activity in the form of an unrestricted educational grant.
The content of this COPE-accredited CE activity was planned and prepared independently by MedEdicus LLC without input from members of an ineligible company.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Sponsored by 
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the State University of New York College of Optometry, MedEdicus LLC, or Dompé US, Inc.
This CE activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 322.2
Available Credit
- 1.50 COPE